A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

NCT ID: NCT06196736

Last Updated: 2025-04-13

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 432 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-12-29
• Study Completion Date: 2027-07-31

Brief Summary

The purpose of this study was to compare the antitumor activity of 9MW2821 and chemotherapy in participants with locally advanced or metastatic urothelial cancer previously treated with PD-(L)1 inhibitor and platinum-containing chemotherapy.

Conditions

Advanced Urothelial Carcinoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

9MW2821

Group Type: EXPERIMENTAL

9MW2821

Intervention Type: DRUG

1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle

Investigator's Choice of Chemotherapy

Group Type: ACTIVE_COMPARATOR

Chemotherapy

Intervention Type: DRUG

75mg/m\^2 docetaxel by intravenous infusion or 175 mg/m\^2 paclitaxel by intravenous infusion on day 1 of every 21-day cycle.

Interventions

9MW2821

1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle

Intervention Type: DRUG

Chemotherapy

75mg/m\^2 docetaxel by intravenous infusion or 175 mg/m\^2 paclitaxel by intravenous infusion on day 1 of every 21-day cycle.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Competent to comprehend, sign, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved informed consent form.

2. Male or female subjects aged 18 to 75 years (including 18 and 75 years).

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

4. Histologically confirmed locally advanced or metastatic urothelial cancer, not amenable to resection with curative intent.

5. Subject must have received a platinum containing chemotherapy and PD-(L)1 inhibitor in the metastatic/locally advanced setting. If platinum and/or PD-(L)1 inhibitor was administered in the adjuvant/neoadjuvant setting subject must have progressed during treatment or within 12 months of completion.

6. Subject must have experienced radiographic progression during or after the last treatment regimen.

7. An archival tumor tissue sample or a fresh tissue sample should be provided.

8. Life expectancy of ≥ 12 weeks.

9. Subjects must have measurable disease according to RECIST (version 1.1).

10. Adequate organ functions.

11. Sexually active fertile subjects, and their partners, must agree to use methods of contraception during the study and at least 6 months after termination of study therapy.

12. Subjects are willing to follow study procedures.

Exclusion Criteria

1. Chemotherapy or radiotherapy within 21 days prior to the first dose of study drug, traditional Chinese medicine with anticancer indication within 14 days prior to the first dose of study drug, use of any investigational drug or device within 28 days prior to the first dose of study drug, received treatment of nectin-4 targeted ADC, received treatment of ADC with MMAE payload, received prior chemotherapy with all available study therapies in the control arm, any strong CYP3A4 inducers/inhibitors within 14 days prior to the first dose of study drug.

2. Preexisting treatment related toxicity Grade ≥ 2 (except alopecia and grade 2 endocrine system toxicity with stable replacement therapy).

3. Major surgery within 28 days prior to first dose of study drug.

4. Hemoglobin A1C (HbA1c) ≥ 8%.

5. Preexisting peripheral neuropathy Grade ≥ 2.

6. Any live vaccines within 28 days before first dose of study drug or during the study.

7. Documented history of clinically significant cardiac or cerebrovascular diseases within 6 months prior to the first dose of study drug.

8. Other severe or uncontrolled disease, i.e. severe respiratory system disease, thromboembolic events, active bleeding or active infection.

9. Central nervous system metastases.

10. History of another malignancy within 3 years before the first dose of study drug. Subjects with cured malignancies are allowed.

11. History of autoimmune disease requiring systemic treatment within 2 years before the first dose of study drug.

12. Has ocular conditions that may increase the risk of corneal epithelium damage.

13. Known sensitivity to any of the ingredients of the investigational product; History of drug abuse or mental illness.

14. Uncontrolled tumor-related bone pain or spinal cord compression. Patients requiring pain medication must be on a stable regimen for at least 2 weeks before the first dose of study drug.

15. Pleural effusion, ascites or pericardial effusion with syptoms or needed drainage.

16. Condition or situation which may put the subject at significant risk.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Dingwei Ye, Professor

Role: CONTACT

fuscc2012@163.com

+8613701663571

Facility Contacts

Ding Ye, Professor

Role: primary

fuscc2012@163.com

+8613701663571

References

Zhang J, Liu R, Wang S, Feng Z, Yang H, Gao S, Li X, Yao X, Chen J, Gong Z, Li Y, Li X, Wang S, Hu C, Liu J, Zhang M, Yuan F, Shi B, Lou H, Zhao P, Qiu F, Guo H, Hu B, Xu D, Huang H, Zhang X, Feng M, Wang X, Li G, Liu D, Chen X, Wang P. Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study. Ann Oncol. 2025 Aug;36(8):934-943. doi: 10.1016/j.annonc.2025.04.009. Epub 2025 Apr 25.

Reference Type: DERIVED

PMID: 40288679 (View on PubMed)

Other Identifiers

9MW2821-2023-CP301

Identifier Type: -

Identifier Source: org_study_id